Dr Ketelbey has more than 30 years’ experience in the healthcare, biotech and pharmaceutical industries, including senior medical and management roles in the Asia Pacific Region with global pharmaceutical company Pfizer.
Dr Ketelbey has a solid track record of product development over his years in the industry leading to the successful registration, launch and commercialisation of numerous market leading medicines in a broad range of therapeutic areas, including in Alzheimer’s disease. Dr Ketelbey led the local clinical development, and was involved in the commercialisation, of Aricept™ (donepezil), the market-leading Alzheimer’s disease therapy.
Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa and a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom. He also has an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors.
Dr. Ketelbey is also a Non-Executive Director of the Westmead Institute of Medical Research (WIMR) and chairs the IP and Commercialisation Committee of WIMR.
LinkedIn Profile: linkedin.com/in/bill-ketelbey-0032098a
Twitter: @BillKetelbey https://twitter.com/billketelbey